Skip to content

2027 at other companies

Azenta logo
AzentaAZTA
Revvity logo
RevvityRVTY
Labcorp Holdings logo
Labcorp HoldingsLH
International Flavors & Fragrances logo
International Flavors & FragrancesIFF

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%
Operating margin-16.7%
Net margin-68.7%
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's 2027?
BioLife Solutions (BLFS) reported 2027 of $1.02M in Q1 2026.
How has BioLife Solutions's 2027 changed year-over-year?
BioLife Solutions's 2027 decreased by 62.3% year-over-year, from $2.69M to $1.02M.